COVID-19

1. Additional resource: bibliography and review found at https://pubs.acs.org/doi/10.1021/acscentsci.0c00272
2. Arabi YM, et al. Am J Respir Crit Care Med 2018;197(6):757-767.
3. Arabi YM, et al. Clin Infect Dis 2019 Jun 25. pii: ciz544.
4. Cao B, et al. N Engl J Med Mar 18.
5. Chu CM, et al. Thorax 2004;59(3):252-6.
6. Cortegiani A, et al. J Crit Care 2020.
7. Gilead Sciences. January, 2020 (https://rdvcu.gilead.com/)
8. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;2021(3). doi:10.1002/14651858.CD013881.
9. Health Canada. Ivermectin not authorized to prevent or treat COVID-19; may cause serious health problems. Recalls and Safety Alerts. Health Canada. Available at: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76365a-eng.php. Accessed September 24, 2021.
10. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/  Accessed September 13, 2021.
11. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA 2021;325:1185-95. doi:10.1001/jama.2021.2747.
12. Lee N, et al. J Clin Virol 2004;31(4):304- 9.
13. Lee N, et al. N Engl J Med 2003;348(20):1986-94.
14. Loutfy MR, et al. JAMA 2003;290(24):3222-8. 
15. Management guidelines from the Public Health Agency of Canada (PHAC), Association of Medical Microbiology and Infectious Diseases (AMMI), Canada/Canadian Critical Care Society (August 17, 2020).  https://canadiancriticalcare.org/resources/Documents/AMMI-CCCS-PHAC-clinical-guidance-Aug21-EN-FINAL.pdf. Accessed Sept 11, 2020.
16. Mulangu S, et al. N Engl J Med 2019;381(24):2293-2303.
17. Nickonchuk T, Kolber MR. Opening a can of helminths: Ivermectin for COVID-19. Tools for Practice #297. September 7, 2021. Available at: https://gomainpro.ca/wp-content/uploads/tools-for-practice/1630698383_tfp297_ivermectin.pdf. Accessed September 24, 2021.
18. Park SY, et al. J Hosp Infect 2019;101(1):42-46.
19. Paton NI, et al. Lancet Infect Dis 2011;11(9):677-83.
20. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med. 2020; NEJMoa2021436. doi:10.1056/NEJMoa2021436.
21. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. [Preprint] medRxiv. doi:10.1101/2021.06.15.21258542.
22. Scientific Advisory Group COVID-19 Recommendations Novel Coronavirus (COVID-19). https://www.albertahealthservices.ca/topics/Page17074.aspx. Accessed Sept 11, 2020.
23. Sheahan TP, et al. Nat Commun 2020;11(1):222.
24. Stockman LJ, et al. PLoS Med 2006;3(9):e343.
25. Sung JJ, et al. Thorax 2004;59(5):414-20.
26. Yao X, et al. Clin Infect Dis 2020 Mar 9, ciaa237.
27. Zumla A, et al. Lancet 2015;386(9997):995-1007.